<bill session="117" type="h" number="7669" updated="2022-12-29T23:48:32Z">
  <state datetime="2022-05-06">REFERRED</state>
  <status>
    <introduced datetime="2022-05-06"/>
  </status>
  <introduced datetime="2022-05-06"/>
  <titles>
    <title type="display">Drug Shortages Shelf Life Extension Act</title>
    <title type="short" as="introduced">Drug Shortages Shelf Life Extension Act</title>
    <title type="official" as="introduced">To require guidance on extending expiration dates for certain drugs, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="M001163"/>
  <cosponsors>
    <cosponsor bioguide_id="B001298" joined="2022-07-15"/>
    <cosponsor bioguide_id="L000582" joined="2022-10-28"/>
    <cosponsor bioguide_id="L000397" joined="2022-09-19"/>
  </cosponsors>
  <actions>
    <action datetime="2022-05-06">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-05-06" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="s" number="3493" relation="unknown"/>
    <bill session="117" type="s" number="3799" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Congressional oversight"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Government information and archives"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Manufacturing"/>
  </subjects>
  <amendments/>
  <summary date="2022-08-08T10:30:22Z" status="Introduced in House">Drug Shortages Shelf Life Extension Act

This bill requires the Food and Drug Administration (FDA) to issue or revise guidance to address issues relating to extending drug expiration dates.

Specifically, the guidance must address recommendations to drug companies relating to (1) submitting stability testing data in applications for market approval for drugs or biological products; (2) establishing on drug labels the longest feasible expiration date scientifically supported by such data, taking into consideration how extended expiration dates may help prevent or mitigate drug shortages and affect product quality; and (3) using innovative approaches to stability modeling to support initial product expiration dates and expiration date extensions.

The FDA must also periodically report to Congress certain information about requests to change the expiration date on a drug label, including the number of such requests from the FDA to the manufacturer and the rationale for each request.</summary>
</bill>
